Akebia Therapeutics
AKBA
73 hedge funds and large institutions have $136M invested in Akebia Therapeutics in 2015 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 38 increasing their positions, 3 reducing their positions, and 9 closing their positions.
1,167% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 3
133% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 9
54% more capital invested
Capital invested by funds: $88.2M → $136M (+$47.5M)
20% more funds holding
Funds holding: 61 → 73 (+12)
11% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $952K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.6M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$10.2M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$5.88M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.4M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$3.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$6.64M |
| 2 |
HM
HealthCor Management
New York
|
-$6.61M |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$221K |
| 4 |
DP
Dearborn Partners
Chicago,
Illinois
|
-$200K |
| 5 |
Swiss National Bank
Zurich,
Switzerland
|
-$191K |
AKBA Hedge Fund Activity: Q2 2015 in Review
73 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q2 2015, worth a combined $136M — up 54% from $88.2M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new AKBA positions and 9 closed out — a net gain of 12 holders — while 38 added to existing stakes and 3 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $10.6M. The largest seller was RA Capital Management, exiting entirely with an estimated $6.64M sold.
- 73 institutional investors held Akebia Therapeutics (AKBA) as of Q2 2015, up from 61 in Q1 2015.
- Funds reported $136M of Akebia Therapeutics stock for Q2 2015, up 54% quarter-over-quarter.
- 21 funds opened new Akebia Therapeutics positions in Q2 2015 and 9 closed out, a net change of +12 holders.
- The largest Akebia Therapeutics buyer in Q2 2015 was Fidelity Investments, an estimated $10.6M added.
- The largest Akebia Therapeutics seller in Q2 2015 was RA Capital Management, an estimated $6.64M sold.
Based on aggregated 13F filings for Q2 2015.